Effects of positive modulators of α-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid (AMPA)-type glutamate receptors in a benzodiazepine-induced deficit of spatial discrimination in mice

Journal of Psychopharmacology

Volumn 26, Issue 6, 2012, Pages 845-856

  Vandesquille, M ^a,b   Carrie I ^a   Louis, C ^a   Beracochea, D ^b   Lestage, P ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Alprazolam amnesia; AMPA; donepezil; memantine; mice; S18986; spatial memory

Indexed keywords

2,3 DIHYDRO 3,4 CYCLOPENTANO 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE; 7 CHLORO 3,4 DIHYDRO 3 METHYL 2H 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE; ALPRAZOLAM; DONEPEZIL; MEMANTINE;

ALLOSTERISM; ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTEROGRADE AMNESIA; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EXPLORATORY BEHAVIOR; MALE; MENTAL TASK; MOTIVATION; MOUSE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; SPATIAL DISCRIMINATION; SPATIAL MEMORY; TASK PERFORMANCE;

ALPRAZOLAM; AMNESIA; ANIMALS; BEHAVIOR, ANIMAL; BENZOTHIADIAZINES; COGNITION DISORDERS; DISCRIMINATION (PSYCHOLOGY); HIPPOCAMPUS; MALE; MEMORY; MICE; MICE, INBRED C57BL; RECEPTORS, AMPA; RECEPTORS, GLUTAMATE; SPATIAL BEHAVIOR;

EID: 84862138083     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111416692     Document Type: Article

References (68)

1. Arai A, Kessler M, Xiao P, Ambros-Ingerson J, Rogers G, Lynch G. A centrally active drug that modulates AMPA receptor gated currents. Brain Res. 1994 ; 638: 343-346
2. Arai AC, Xia YF, Suzuki E. Modulation of AMPA receptor kinetics differentially influences synaptic plasticity in the hippocampus. Neuroscience. 2004 ; 123: 1011-1024
3. Aronica E, Dickson DW, Kress Y, Morrison JH, Zukin RS. Non-plaque dystrophic dendrites in Alzheimer hippocampus: a new pathological structure revealed by glutamate receptor immunocytochemistry. Neuroscience. 1998 ; 82: 979-991
4. Auta J, Faust WB, Lambert P, Guidotti A, Costa E, Moerschbaecher JM. Comparison of the effects of full and partial allosteric modulators of GABA(A) receptors on complex behavioral processes in monkeys. Behav Pharmacol. 1995 ; 6: 323-332
5. Barnes CA, Danysz W, Parsons CG. Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur J Neurosci. 1996 ; 8: 565-571
6. Barnes CA, Meltzer J, Houston F, Orr G, McGann K, Wenk GL. Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience. 2000 ; 99: 17-23
7. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982 ; 217: 408-414
8. Beracochea D. Anterograde and retrograde effects of benzodiazepines on memory. Sci World J. 2006 ; 6: 1460-1465
9. Beracochea D, Boucard A, Trocme-Thibierge C, Morain P. Improvement of contextual memory by S 24795 in aged mice: comparison with memantine. Psychopharmacology. 2008 ; 196: 555-564
10. Beracochea D, Philippin JN, Meunier S, Morain P, Bernard K. Improvement of episodic contextual memory by S 18986 in middle-aged mice: comparison with donepezil. Psychopharmacology. 2007 ; 193: 63-73
11. Bertaina-Anglade V, Enjuanes E, Morillon D, Drieu La Rochelle C. The object recognition task in rats and mice: a simple and rapid model in safety pharmacology to detect amnesic properties of a new chemical entity. J Pharmacol Toxicol Methods. 2006 ; 54: 99-105
12. Black MD. Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. Psychopharmacology. 2005 ; 179: 154-163
13. Bontempi B, Whelan KT, Risbrough VB, Lloyd GK, Menzaghi F. Cognitive enhancing properties and tolerability of cholinergic agents in mice: a comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors. Neuropsychopharmacology. 2003 ; 28: 1235-1246
14. Buccafusco JJ, Weiser T, Winter K, Klinder K, Terry AV. The effects of IDRA-21, a positive modulator of the AMPA receptor, on delayed matching performance by young and aged rhesus monkeys. Neuropharmacology. 2004 ; 46: 10-22
15. Chalmers DT, Dewar D, Graham DI, Brooks DN, McCulloch J. Differential alterations of cortical glutamatergic binding sites in senile dementia of the Alzheimer type. Proc Natl Acad Sci U S A. 1990 ; 87: 1352-1356
16. Célérier A, Piérard C, Rachbauer D, Sarrieau A, Béracochéa D. Contextual and serial discriminations: a new learning paradigm to assess simultaneously the effects of acute stress on retrieval of flexible or stable information in mice. Learn Mem. 2004 ; 11: 196-204
17. Chen Y, Byrne P, Crawford JD. Time course of allocentric decay, egocentric decay, and allocentric-to-egocentric conversion in memory-guided reach. Neuropsychologia. 2011 ; 49: 49-60
18. Creeley C, Wozniak DF, Labruyere J, Taylor GT, Olney JW. Low doses of memantine disrupt memory in adult rats. J Neurosci. 2006 ; 26: 3923-3932
19. Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003 ; 18: S23 - S32
20. Danysz W, Parsons CG, Mobius HJ, Stoffler A, Quack G. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease-a unified glutamatergic hypothesis on the mechanism of action. Neurotox Res. 2000 ; 2: 85-97
21. Destot-Wong KD, Liang K, Gupta SK, Favrais G, Schwendimann L, Pansiot J, et al. The AMPA receptor positive allosteric modulator, S18986, is neuroprotective against neonatal excitotoxic and inflammatory brain damage through BDNF synthesis. Neuropharmacology. 2009 ; 57: 277-286
22. Downey D. Pharmacologic management of Alzheimer disease. J Neurosci Nurs. 2008 ; 40: 55-59
23. Eustache F, Giffard B, Rauchs G, Chetelat G, Piolino P, Desgranges B. Alzheimer's disease and human memory. Rev Neurol. 2006 ; 162: 929-939
24. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005 ; 366: 2112-2117
25. Fletcher EJ, Lodge D. New developments in the molecular pharmacology of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate and kainate receptors. Pharmacol Ther. 1996 ; 70: 65-89
26. Francis PT. The interplay of neurotransmitters in Alzheimer's disease. CNS Spectr. 2005 ; 11 (18). 6-9
27. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999 ; 66: 137-147
28. Francis PT, Sims NR, Procter AW, Bowen DM. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives. J Neurochem. 1993 ; 60: 1589-1604
29. Giusti P, Guidetti G, Costa E, Guidotti A. The preferential antagonism of pentylenetetrazole proconflict responses differentiates a class of anxiolytic benzodiazepines with potential antipanic action. J Pharmacol Exp Ther. 1991 ; 257: 1062-1068
30. Hogan JB, Hodges DB, Lelas S, Gilligan PJ, McElroy JF, Lindner MD. Effects of CRF1 receptor antagonists and benzodiazepines in the Morris water maze and delayed nonmatching to position tests. Psychopharmacology. 2005 ; 178: 410-419
31. Ikonomovic MD, Sheffield R, Armstrong DM. AMPA-selective glutamate receptor subtype immunoreactivity in the aged human hippocampal formation. J Comp Neurol. 1995 ; 359: 239-252
32. IkonomovicMDMizukamiKWardeDSheffieldRHamiltonRWentholdRJArmstrongDM (1999) Distribution of glutamate receptor subunit NMDAR1 in the hippocampus of normal elderly and patients with Alzheimer's disease. Exp Neurol160: 194-204.
33. Lebrun C, Pillière E, Lestage P. Effects of S 18986-1, a novel cognitive enhancer, on memory performances in an object recognition task in rats. Eur J Pharmacol. 2000 ; 401: 205-212
34. Lepagnol J. Physiopathologic mechanisms in acute progressive neuronal death: pharmacotherapeutic consequences. J Pharm Belg. 1997 ; 52: 100-101
35. Lestage P. Pharmacologic treatment for cognitive disorders: an update. Therapie. 2000 ; 55: 507-512
36. Lindner MD, Hogan JB, Hodges DB, Orie AF, Chen P, Corsa JA, et al. Donepezil primarily attenuates scopolamine-induced deficits in psychomotor function, with moderate effects on simple conditioning and attention, and small effects on working memory and spatial mapping. Psychopharmacology (Berl). 2006 ; 188: 629-640
37. Lockhart B, Iop F, Closier M, Lestage P. (S)-2,3-dihydro-[3,4] cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide: (S18986-1) a positive modulator of AMPA receptors enhances (S)-AMPA-mediated [3H]noradrenaline release from rat hippocampal and frontal cortex slices. Eur J Pharmacol. 2000 ; 401: 145-153
38. Lockhart BP, Lestage PJ. Cognition enhancing or neuroprotective compounds for the treatment of cognitive disorders: why? when? which?. Exp Gerontol. 2003 ; 38: 119-128
39. Lockrow J, Boger H, Bimonte-Nelson H, Granholm AC. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav Brain Res. 2011 ; 221: 610-622
40. Lowe SL, Francis PT, Procter AW, Palmer AM, Davison AN, Bowen DM. Gamma-aminobutyric acid concentration in brain tissue at two stages of Alzheimer's disease. Brain. 1988 ; 111: 785-799
41. Martinez-Coria H, Green KN, Billings LM, Kitazawa M, Albrecht M, Rammes G, et al. Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol. 2010 ; 176: 870-880
42. Minkeviciene R, Banerjee P, Tanila H. Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease. J Pharmacol Exp Ther. 2004 ; 311: 677-682
43. Nyakas C, Granic I, Halmy LG, Banerjee P, Luiten PG. The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-β42 with memantine. Behav Brain Res. 2011 ; 221: 594-603
44. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007 ; 55: 697-711
45. Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology. 2007 ; 53: 699-723
46. Rissman RA, Bennett DA, Armstrong DM. Subregional analysis of GABA(A) receptor subunit mRNAs in the hippocampus of older persons with and without cognitive impairment. J Chem Neuroanat. 2004 ; 28: 17-25
47. Rissman RA, De Blas AL, Armstrong DM. GABA(A) receptors in aging and Alzheimer's disease. J Neurochem. 2007 ; 103: 1285-1292
48. Robbins TW, Murphy ER. Behavioural pharmacology: 40+ years of progress, with a focus on glutamate receptors and cognition. Trends Pharmacol Sci. 2006 ; 27: 141-148
49. Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 2003 ; 9: 275-308
50. Rosi S, Giovannini MG, Lestage PJ, Muñoz C, Corte LD, Pepeu G. S 18986, a positive modulator of AMPA receptors with cognition-enhancing properties, increases ACh release in the hippocampus of young and aged rat. Neurosci Lett. 2004 ; 361: 120-123
51. Ruano D, Araujo F, Revilla E, Vela J, Bergis O, Vitorica J. GABAA and alpha-amino-3-hydroxy-5-methylsoxazole-4-propionate receptors are differentially affected by aging in the rat hippocampus. J Biol Chem. 2000 ; 275: 19585-19593
52. Rudolph U, Möhler H. GABA-based therapeutic approaches: GABAA receptor subtype functions. Curr Opin Pharmacol. 2006 ; 6: 18-23
53. Seltzer B. Donepezil: an update. Expert Opin Pharmacother. 2007 ; 8: 1011-1023
54. Singh N, Sharma A, Singh M. Possible mechanism of alprazolam-induced amnesia in mice. Pharmacology. 1998 ; 56: 46-50
55. Sun B, Halabisky B, Zhou Y, Palop JJ, Yu G, Mucke L, Gan L. Imbalance between GABAergic and glutamatergic transmission impairs adult neurogenesis in an animal model of Alzheimer's disease. Cell Stem Cell. 2009 ; 5: 624-633
56. Thiebot MH. Some evidence for amnesic-like effects of benzodiazepines in animals. Neurosci Biobehav Rev. 1985 ; 9: 95-100
57. Thompson DM, Guidotti A, DiBella M, Costa E. 7-Chloro-3-methyl-3,4- dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide (IDRA-21), a congener of aniracetam, potently abates pharmacologically induced cognitive impairments in patas monkeys. Proc Natl Acad Sci U S A. 1995 ; 92: 7667-7671
58. Van Dam D, Abramowski D, Staufenbiel M, De Deyn PP. Symptomatic effects of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology. 2005 ; 180: 177-190
59. Vandesquille M, Krazem A, Louis C, Lestage P, Beracochea D. S18986 reverses spatial working memory impairments in aged mice: comparison with memantine. Psychopharmacology. 2011 ; 215: 709-720
60. Vela J, Gutierrez A, Vitorica J, Ruano D. Rat hippocampal GABAergic molecular markers are differentially affected by ageing. J Neurochem. 2003 ; 85: 368-377
61. Wan H, Warburton EC, Zhu XO, Koder TJ, Park Y, Aggleton JP, et al. Benzodiazepine impairment of perirhinal cortical plasticity and recognition memory. Eur J Neurosci. 2004 ; 20: 2214-2224
62. Westphalen RI, Scott HL, Dodd PR. Synaptic vesicle transport and synaptic membrane transporter sites in excitatory amino acid nerve terminals in Alzheimer's disease. J Neural Transm. 2003 ; 110: 1013-1027
63. Yamada KA. Therapeutic potential of positive AMPA receptor modulators in the treatment of neurological disease. Expert Opin Investig Drugs. 2000 ; 9: 765-778
64. Yoshiike Y, Kimura T, Yamashita S, Furudate H, Mizoroki T, Murayama M, et al. GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin. PLoS One. 2008 ; 3: e3029
65. Zajaczowski W, Frankiewicz T, Parsons CG, Danysz W. Uncompetitive NMDA receptor antagonists attenuate NMDA induced impairment of passive avoidance learning and LTP. Neuropharmacology. 1997 ; 36: 961-976
66. ZhaoCDengWGageFH (2008) Mechanisms and functional implications of adult neurogenesis. Cell132: 645-660.
67. Zivkovic I, Thompson DM, Bertolino M, Uzunov D, DiBella M, Costa E, et al. 7-Chloro-3-methyl-3-4-dihydro-2H-1,2,4 benzothiadiazine S,S-dioxide (IDRA-21): a benzothiadiazine derivative that enhances cognition by attenuating DL-alpha-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid (AMPA) receptor desensitization. J Pharmacol Exp Ther. 1995 ; 272: 300-309
68. Zoladz PR, Campbell AM, Collin RP, Schaefer D, Danysz W, Diamond DM. Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane. Pharmacol Biochem Behav. 2006 ; 85: 298-306